Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Georgina V. Long, Reinhard Dummer, Omid Hamid, Thomas Gajewski, Christian Caglevic, Stéphane Dalle, Ana Arance, Matteo S. Carlino, Jean-Jacques Grob, Tae Min Kim, Lev V. Demidov, Caroline Robert, James M. G. Larkin, James Anderson, Janet E. Maleski, Mark M. Jones, Scott J. Diede, Tara C. Mitchell
Institutions: The University of Sydney, Royal North Shore Hospital, Melanoma Institute Australia, University of Zurich, University Hospital Zurich, Angeles Clinic and Research Institute, University of Chicago Medical Center, Fundación Arturo López Pérez, Hospices Civils de Lyon, Assistance Publique Hôpitaux de Marseille, Hôpital de la Timone, Seoul National University Hospital, Russian Cancer Research Center NN Blokhin, Institut Gustave Roussy, Royal Marsden Hospital, Merck & Co., Inc., Rahway, NJ, USA (United States), Incyte (United States), Abramson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2807361763